[go: up one dir, main page]

MX2021006010A - Formulaciones farmaceuticas para analogos de ciclosporina. - Google Patents

Formulaciones farmaceuticas para analogos de ciclosporina.

Info

Publication number
MX2021006010A
MX2021006010A MX2021006010A MX2021006010A MX2021006010A MX 2021006010 A MX2021006010 A MX 2021006010A MX 2021006010 A MX2021006010 A MX 2021006010A MX 2021006010 A MX2021006010 A MX 2021006010A MX 2021006010 A MX2021006010 A MX 2021006010A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
cyclosporine analogs
cyclosporine
analogs
stability
Prior art date
Application number
MX2021006010A
Other languages
English (en)
Inventor
Daniel Joseph Trepanier
Daren Raymond Ure
Robert Thomas Foster
Original Assignee
Hepion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hepion Pharmaceuticals Inc filed Critical Hepion Pharmaceuticals Inc
Publication of MX2021006010A publication Critical patent/MX2021006010A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación se refiere a composiciones farmacéuticas que comprenden CRV431 o una sal farmacéuticamente aceptable del mismo. Las composiciones exhiben alta solubilidad y estabilidad.
MX2021006010A 2018-11-26 2019-11-22 Formulaciones farmaceuticas para analogos de ciclosporina. MX2021006010A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862771453P 2018-11-26 2018-11-26
PCT/US2019/062849 WO2020112562A1 (en) 2018-11-26 2019-11-22 Pharmaceutical formulations of cyclosporine analogs

Publications (1)

Publication Number Publication Date
MX2021006010A true MX2021006010A (es) 2021-09-21

Family

ID=68916602

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006010A MX2021006010A (es) 2018-11-26 2019-11-22 Formulaciones farmaceuticas para analogos de ciclosporina.

Country Status (28)

Country Link
US (3) US20200163876A1 (es)
EP (1) EP3886813B1 (es)
JP (1) JP7489385B2 (es)
KR (1) KR20210099038A (es)
CN (1) CN113194927B (es)
AR (1) AR117150A1 (es)
AU (1) AU2019386859A1 (es)
BR (1) BR112021009967A2 (es)
CA (1) CA3120015A1 (es)
CY (1) CY1126071T1 (es)
DK (1) DK3886813T3 (es)
ES (1) ES2942473T3 (es)
FI (1) FI3886813T3 (es)
HR (1) HRP20230548T1 (es)
HU (1) HUE061877T2 (es)
IL (1) IL283286A (es)
LT (1) LT3886813T (es)
MX (1) MX2021006010A (es)
PH (1) PH12021551086A1 (es)
PL (1) PL3886813T3 (es)
PT (1) PT3886813T (es)
RS (1) RS64239B1 (es)
SG (1) SG11202105336TA (es)
SI (1) SI3886813T1 (es)
SM (1) SMT202300139T1 (es)
TW (1) TWI844585B (es)
WO (1) WO2020112562A1 (es)
ZA (1) ZA202103090B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022010201A (es) 2020-02-19 2022-09-19 Hepion Pharmaceuticals Inc Uso de analogos de ciclosporina para el tratamiento de la fibrosis.
US20210269479A1 (en) 2020-02-25 2021-09-02 Hepion Pharmaceuticals, Inc. Use of cyclosporine analogues for treating cancer
US20220168385A1 (en) 2020-11-29 2022-06-02 Hepion Pharmaceuticals, Inc. Use of cyclosporine analogues as antithrombotic agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US6262022B1 (en) * 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
EP1408930A1 (de) * 1999-10-20 2004-04-21 Vesifact Ag Cyclosporine enthaltende mikroemulsion-prekonzentrate und mikroemulsionen
HUP0400263A2 (hu) * 2001-06-21 2005-03-29 Pfizer Products Inc. Koleszteril-észter transzfer protein inhibitort tartalmazó önemulgeáló készítmény
PT1435910E (pt) * 2001-10-19 2009-09-07 Isotechnika Inc Novos pré-concentrados de microemulsão de análogos da ciclosporina
US20180296588A1 (en) * 2017-04-14 2018-10-18 Contravir Pharmaceuticals, Inc. Combination therapy for treating viral infections

Also Published As

Publication number Publication date
SMT202300139T1 (it) 2023-07-20
US20200163876A1 (en) 2020-05-28
SI3886813T1 (sl) 2023-05-31
LT3886813T (lt) 2023-04-11
CA3120015A1 (en) 2020-06-04
IL283286A (en) 2021-07-29
HRP20230548T1 (hr) 2023-08-04
BR112021009967A2 (pt) 2021-08-17
CN113194927B (zh) 2023-10-27
CN113194927A (zh) 2021-07-30
TW202038911A (zh) 2020-11-01
PL3886813T3 (pl) 2023-06-19
ES2942473T3 (es) 2023-06-01
WO2020112562A1 (en) 2020-06-04
EP3886813B1 (en) 2023-03-22
SG11202105336TA (en) 2021-06-29
US20230390199A1 (en) 2023-12-07
KR20210099038A (ko) 2021-08-11
CY1126071T1 (el) 2023-11-15
PH12021551086A1 (en) 2022-01-03
TWI844585B (zh) 2024-06-11
ZA202103090B (en) 2023-09-27
AR117150A1 (es) 2021-07-14
EP3886813A1 (en) 2021-10-06
HUE061877T2 (hu) 2023-08-28
PT3886813T (pt) 2023-04-26
DK3886813T3 (da) 2023-05-01
RS64239B1 (sr) 2023-06-30
JP2022513635A (ja) 2022-02-09
AU2019386859A1 (en) 2021-05-27
FI3886813T3 (fi) 2023-05-04
JP7489385B2 (ja) 2024-05-23
US20230390198A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MX2024013464A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
NZ763123A (en) Pde9 inhibitor and use thereof
MX2021006969A (es) Ligante peptidico.
ZA202103090B (en) Pharmaceutical formulations of cyclosporine analogs
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
WO2020009675A3 (en) Solid oral pharmaceutical compositions of linagliptin
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2023012198A (es) Composiciones de amantadina, preparaciones de estas y metodos de uso.
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
WO2020068657A8 (en) 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
ZA202107580B (en) Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability
WO2019151964A3 (en) Orally disintegrating formulations of saxagliptin
WO2019209217A3 (en) Modified release formulations of flurbiprofen
EA202091561A1 (ru) Фармацевтическая композиция, содержащая фармацевтически приемлемую кислотно-аддитивную соль леналидомида
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
MX2018010652A (es) Composiciones farmaceuticas.
PH12016502527A1 (en) Stabilized desmopressin
WO2020018034A3 (en) Oral pharmaceutical compositions comprising dpp-4 inhibitor
TR201722852A2 (tr) Mesalazi̇ni̇n oral farmasöti̇k kompozi̇syonlari